An injection of stem cells into the eye may soon slow or reverse the effects of early-stage age-related macular degeneration, according to new research from scientists at Cedars-Sinai
Currently, there is no treatment that slows the progression of the disease, which is the leading cause of vision loss in people over 65.
“This is the first study to show preservation of vision after a single injection of adult-derived human cells into a rat model with age-related macular degeneration,” said Shaomei Wang, MD, PhD, lead author of the study published in the journal STEM CELLS and a research scientist in the Eye Program at the Cedars-Sinai Board of Governors Regenerative Medicine Institute.
The stem cell injection resulted in 130 days of preserved vision in laboratory rats, which roughly equates to 16 years in humans.
Age-related macular degeneration affects upward of 15 million Americans. It occurs when the small central portion of the retina, known as the macula, deteriorates. The retina is the light-sensing nerve tissue at the back of the eye. Macular degeneration may also be caused by environmental factors, aging and a genetic predisposition.
When animal models with macular degeneration were injected with induced neural progenitor stem cells, which derive from the more commonly known induced pluripotent stem cells, healthy cells began to migrate around the retina and formed a protective layer. This protective layer prevented ongoing degeneration of the vital retinal cells responsible for vision.
Cedars-Sinai researchers in the Induced Pluripotent Stem Cell (iPSC) Core, directed by Dhruv Sareen, PhD, with support from the David and Janet Polak Foundation Stem Cell Core Laboratory, first converted adult human skin cells into powerful induced pluripotent stem cells (iPSC), which can be expanded indefinitely and then made into any cell of the human body. In this study, these induced pluripotent stem cells were then directed toward a neural progenitor cell fate, known as induced neural progenitor stem cells, or iNPCs.
“These induced neural progenitor stem cells are a novel source of adult-derived cells which should have powerful effects on slowing down vision loss associated with macular degeneration,” said Clive Svendsen, PhD, director of the Board of Governors Regenerative Medicine Institute and contributing author to the study. “Though additional pre-clinical data is needed, our institute is close to a time when we can offer adult stem cells as a promising source for personalized therapies for this and other human diseases.”
The Latest on: Age-Related Macular Degeneration
via Google News
The Latest on: Age-Related Macular Degeneration
- AI Systems Predict the Course of Macular Degenerationon May 27, 2020 at 11:33 am
Two new artificial intelligence algorithms can predict the development of age-related macular degeneration, researchers say.
- AI model predicts risk for age-related macular degenerationon May 27, 2020 at 10:46 am
A new artificial intelligence algorithm can predict risk for age-related macular degeneration (AMD), according to a study published in the April issue of Translational Vision Science and Technology.
- What you should know about COVID-19 and blinding eye diseaseson May 27, 2020 at 3:27 am
At the (AMDF), we have been thinking a lot about how many people with age-related macular degeneration (AMD) may be concerned about being more at-risk from COVID-19. To address concerns regarding AMD ...
- Roche: Port Delivery System With Ranibizumab Shows Positive Trial Results In NAMDon May 26, 2020 at 10:54 pm
Port Delivery System with ranibizumab or PDS is a permanent refillable eye implant, approximately the size of a grain of rice, which continuously delivers a customised formulation of ranibizumab over ...
- Port Delivery System With Ranibizumab Shows Positive Phase III Results in Neovascular Age-Related Macular Degenerationon May 26, 2020 at 10:31 pm
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY) today announced positive topline results from the Phase III Archway study, evaluat ...
- Roche's Port Delivery System with ranibizumab shows positive phase III results in neovascular age-related macular degenerationon May 26, 2020 at 10:00 pm
Port Delivery System with ranibizumab (PDS) is a permanent refillable eye implant that continuously delivers ranibizumab over a period of months, potentially reducing ...
- Macular Degeneration Treatment Market Trends, Size, Forecast - 2019-2025on May 26, 2020 at 1:57 am
The global macular degeneration treatment market is estimated to grow at a CAGR of nearly 7 0 during the forecast period Due to the increasing geriatric population and the rising incidences of age ...
- Scientists discover cause of leakiness in eye diseaseson May 25, 2020 at 3:47 am
In a new study, researchers have identified a key step in the process that leads to leaky vessels and harmful swelling in eye diseases. The discovery could lead to improved treatments for diseases ...
- Age-Related Macular Degeneration: Study Finds Surprising Culpriton May 18, 2020 at 7:43 pm
A new study suggests that a molecule that usually suppresses harmful blood vessel growth may do the opposite in a type of sight loss called age-related macular degeneration (AMD). If confirmed in ...
- Macular Degeneration Treatment Market is Anticipated to Reach US$ 11.1 Bn by 2026on May 18, 2020 at 6:53 am
TMR has published a new report titled Macular degeneration treatment Market Global Industry Analysis Size Share Growth Trends and Forecast 2018 2026 According to the report the global macular ...
via Bing News